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Muscle myeloid type I interferon gene expression
may predict therapeutic responses to rituximab
in myositis patients
Kanneboyina Nagaraju1,2, Svetlana Ghimbovschi1, Sree Rayavarapu1,2,
Aditi Phadke1, Lisa G. Rider3, Eric P. Hoffman1,2 and Frederick W. Miller3
Abstract
Objective. To identify muscle gene expression patterns that predict rituximab responses and assess the
effects of rituximab on muscle gene expression in PM and DM.
Methods. In an attempt to understand the molecular mechanism of response and non-response to
rituximab therapy, we performed Affymetrix gene expression array analyses on muscle biopsy specimens
taken before and after rituximab therapy from eight PM and two DM patients in the Rituximab in Myositis
study. We also analysed selected muscle-infiltrating cell phenotypes in these biopsies by immunohisto-
chemical staining. Partek and Ingenuity pathway analyses assessed the gene pathways and networks.
Results. Myeloid type I IFN signature genes were expressed at higher levels at baseline in the skeletal
muscle of rituximab responders than in non-responders, whereas classic non-myeloid IFN signature genes
were expressed at higher levels in non-responders at baseline. Also, rituximab responders have a greater
reduction of the myeloid and non-myeloid type I IFN signatures than non-responders. The decrease in the
type I IFN signature following administration of rituximab may be associated with the decreases in muscle-
infiltrating CD19+ B cells and CD68+ macrophages in responders.
Conclusion. Our findings suggest that high levels of myeloid type I IFN gene expression in skeletal muscle
predict responses to rituximab in PM/DM and that rituximab responders also have a greater decrease in
the expression of these genes. These data add further evidence to recent studies defining the type I IFN
signature as both a predictor of therapeutic responses and a biomarker of myositis disease activity.
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Rheumatology key messages
. PM/DM patients who responded to rituximab had higher levels of myeloid type I IFN pathway gene expression in
muscle.
. Rituximab responders had a greater decrease in the expression of myeloid type I IFN genes.
. Type I IFN signalling in skeletal muscle cells may play a role in the pathogenesis of myositis.
Introduction
PM and DM are characterized by chronic inflammation in
the muscle and the frequent finding of selected autoan-
tibodies [1]. Immunosuppressive medications are cur-
rently used as therapies for these conditions, however,
a large number of patients do not respond completely to
the current therapies. A randomized, double-blind, pla-
cebo-controlled clinical trial was conducted to assess
the efficacy of rituximab in refractory adult and juvenile
myositis patients using validated measures of disease
activity and a data- and consensus-driven definition of
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improvement (DOI) [2]. Although there were no statistic-
ally significant differences in the primary or secondary
endpoints between the two treatment arms, 83% of re-
fractory adult and juvenile myositis patients met the DOI
[3]. Clinical response to rituximab in myositis (RIM) has
been predicted by anti-synthetase and anti-Mi-2 autoan-
tibodies [4].
Likewise, recent studies indicate that the type I IFN
gene and chemokine scores and the levels of pro-
inflammatory cytokines (IL-6, IL-8 and TNF-a) may
serve as sensitive and responsive longitudinal bio-
markers of change in disease activity in juvenile and
adult DM [5]. Type I IFN originates from as well as affects
both myeloid and non-myeloid cells. Innate immune
myeloid cells rapidly respond to inflammatory stimuli in
injured tissues, including skeletal muscle. It is well known
that type I IFN signalling significantly alters dynamics of
myeloid cells in the injured tissues. For example, Type I
IFN initiates arrival of innate myeloid cells in the brains of
lymphocytic choriomeningitis virus (LCMV)-infected
mice. Over a period of time, the myeloid cell population
decreases and returns to a near-normal state in the
LCMV-infected brains. This decrease in myeloid cell
population coincides with reduced type I IFN production,
suggesting type I IFN signalling is responsible for innate
myeloid cell dynamics. In fact, LCMV-infected brains of
IFNR null mice behave like mock-infected controls, sug-
gesting type I IFN signalling completely controls innate
immune activity in injured tissues [6]. Therefore, we pro-
pose that therapies that aim to reduce inflammation
should reduce myeloid cells as well as the myeloid type
I IFN signature.
To assess the mechanism of response and non-
response to rituximab therapy, we performed the first
muscle gene expression profiling and analyses before
and after treatment in refractory PM and DM patients.
Since myeloid cells are known to significantly contribute
to type I IFN signature, we specifically investigated the
responsiveness of myeloid- and non-myeloid-associated
type I IFN signatures in these patients.
Methods
Patients
Treatment-refractory adult PM and adult and juvenile DM
patients meeting probable or definite Bohan and Peter
criteria and with evidence of moderate disease activity re-
fractory to prednisone and at least one other agent were
enrolled into this institutional review boardapproved
study [3]. Adult subjects (eight with PM, two with DM)
enrolled at the National Institutes of Health and who
agreed to have research muscle biopsies underwent sur-
gical thigh muscle biopsies pre- and post-rituximab ther-
apy. This study was approved by the National Institute of
Diabetes and Digestive and Kidney Diseases/National
Institute of Arthritis and Musculoskeletal and Skin
Diseases institutional review board, and all patients
signed informed consent in accordance with the Helsinki
Declaration.
In this trial, a baseline muscle biopsy was done just prior
to rituximab treatment at week 0 and the follow-up biopsy
was done at week 16. The randomized placebo-controlled
design involved group A receiving rituximab at weeks 0
and 1 and group B receiving it at weeks 8 and 9; both
groups were included in our results. Although there were
differences in the number of weeks post-therapy before
the biopsy, there were no significant differences in the
findings between the groups. Muscle biopsy specimens
were flash-frozen in liquid nitrogencooled isopentane
and then stored at 80ºC until use. Clinical response to
rituximab was measured by meeting the DOI at week 16.
Concomitant therapy with other immunosuppressive
agents (prednisone, MTX, AZA or HCQ) was equally dis-
tributed between the responder and non-responder
groups (Table 1).
RNA extraction and gene expression profiling
Muscle biopsy samples were subjected to total RNA iso-
lation by use of TRIzol reagent (Invitrogen, Carlsbad, CA,
USA) followed by the RNeasy MiniElute clean-up kit, and
the quality of the RNA samples was assessed with an
TABLE 1 Demographics, response status and other selected features of myositis patients
Patient
no.
Age,
years Gender DX Respondera
Anti-Jo-1 or SRP
autoantibody
present Therapy
1 75 F DM No None PD, PQ, AZA
2 59 M PM No None PD, AZA
3 70 F PM No None PD, MTX
4 42 F PM No SRP PD, MTX
5 66 F PM No None PD, MTX, AZA
6 50 F PM Yes None PD, MTX, AZA
7 46 F PM Yes Jo-1 PD, MTX
8 48 M DM Yes SRP PD, MTX, AZA
9 74 F PM Yes Jo-1 PD, MTX
10 60 F PM Yes SRP PD, MTX, AZA
aResponders or non-responders to treatment as determined by the primary definition of improvement at week 16. Dx: diag-
nosis; PD: prednisone; PQ: plaquenil.
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Agilent 2100 Bioanalyzer (Agilent Technologies., Santa
Clara, CA, USA). Gene expression profiling was performed
using the GeneChip approach (Affymetrix, Santa Clara,
CA, USA).
Partek and Ingenuity pathway analyses
To generate expression values for probe sets, GeneChip-
derived CEL files were analysed with the Probe
Logarithmic Intensity Error algorithm in Expression
Console software (Affymetrix, Santa Clara, CA, USA).
Probe Logarithmic Intensity Error algorithmderived
probe sets’ signal intensity values were uploaded directly
into the Partek Genomics Suite, version 6.5 (Partek, St
Louis, MO, USA) for statistics and data visualization.
Differences in gene expression levels between responder
and non-responder patients before treatment (at baseline)
were analysed using a one-way ANOVA model. A para-
metric paired-sample t-test was used to test the signifi-
cance of differences in gene expression levels before and
after RIM treatment between patients, who did or did not
respond to the treatment. To identify significant molecular
networks and pathways, we used an Ingenuity Pathways
Analysis software application (Ingenuity Systems,
Redwood City, CA, USA). After this analysis, networks
generated were ordered by a score denoting significance.
Immunohistochemical staining
Frozen human muscle biopsy specimens of myositis (PM
and DM patients; n = 8 and 2, respectively) were obtained
before and after rituximab treatment. Muscle tissues were
sectioned and fixed in ice-cold acetone for 5 min, and
immunostaining was performed using the Vectastain
Elite ABC kit (Vector Laboratories, Burlingame, CA, USA)
using monoclonal mouse anti-human CD19 (Dako,
Carpinteria, CA, USA) (1:50 dilution), monoclonal mouse
anti-human CD68 (Dako) (1:50 dilution), monoclonal
mouse anti-human CD138 (Dako) (1:50 dilution), rabbit
anti-IPS1, rabbit IFN-b (Millipore, Billerica, MA, USA),
rabbit anti-human MX1 (GeneTex, Irvine, CA, USA) and
horseradish peroxidaseconjugated polyclonal rabbit
anti-mouse immunoglobulins (Dako) as the primary and
secondary antibodies, respectively. A semi-quantitative
immunophenotyping assessment of entire stained sec-
tions was done in a blinded fashion using a 05 scale.
Sections with the highest amount of inflammatory infiltrate
(>20%) were given a score of 5, 1520% inflammation a
score of 4, 1015% inflammation a score of 3, 510%
inflammation a score of 2, <5% inflammation a score of
1 and sections with no inflammatory cells were given a
score of 0.
Results
Type I IFN signature genes and their clusters are
differentially expressed in muscle biopsies from
rituximab non-responder and responder patients
We stratified patients on the basis of the DOI criteria at
week 16 [2, 3] into rituximab responder and non-
responder groups (Table 1). Microarray analysis of gene
expression changes in the skeletal muscle of myositis pa-
tients before and after rituximab treatment showed differ-
ential expression of innate immune and inflammatory
genes. Most striking among these genes were type I IFN
genes (Fig. 1A). These genes are known to have immuno-
modulatory effects on the infiltrating immune cells as well
as skeletal muscle. Since previous reports have also indi-
cated that the type I IFN gene signature score is
correlated with disease activity in adult and juvenile myo-
sitis patients [5, 7, 8], we selected 37 type I IFN signature
genes that represent broad innate immune anti-
proliferative functions. Relative expression patterns of
these genes varied significantly between responder and
non-responder groups. Supervised hierarchical clustering
analysis of these genes resulted in five distinct clusters,
including myeloid clusters (clusters 1 and 2) and non-
myeloid clusters (clusters 35) (Fig. 1BD).
Cluster 1 gene expression, consisting of the STAT4,
SDC1, ITGB8, MAVS, RFX3, IFNAR2, IRF4, UBA7 and
IFRD1 genes, was elevated in the muscle tissue of the
responder group prior to rituximab treatment and was
decreased post-treatment, whereas the expression of
this gene cluster was low in the non-responder group in
both the pre- and post-treatment muscle samples. Cluster
2 gene expression, consisting of the ICAM1, IRF1,
CASP2, SIGLEC1, CD68 and IFI44 genes, was increased
in both the pre- and post-treatment muscle biopsies from
patients showing a clinical response, whereas the
expression of this cluster was low in both the pre- and
post-treatment samples from the non-responder group
(Fig. 1B). Cluster 3 gene expression, consisting of the
CD19, IFI35, IFNA1, MX2, UBE2L6, LY6E, XAF1 and
SP110 genes, was high in the muscle of the non-
responder group prior to treatment with rituximab and
decreased post-treatment, whereas the expression of
this gene cluster was low in the responder group in both
the pre- and post-treatment samples. Cluster 4 gene ex-
pression, consisting of the OAS1, USP18, ISG15, IFIT5,
MEG3, RTP4, MX1, OAS3 and IFNA2 genes, was
increased in pre- and post-treatment non-responders,
whereas the expression of this cluster was low in the re-
sponder group in both the pre- and post-treatment sam-
ples. Cluster 5 gene expression, consisting of the OAS2,
OASL, IFIT3, IFIT2 and IFNB1 genes, was increased in
post-treatment non-responders and low in pre- and
post-treatment responders (Fig. 1C). Unsupervised com-
parison of all samples before rituximab treatment indi-
cates that the subjects cluster into two groups
(responder vs non-responder) even before treatment (sup-
plementary Fig. S1, available at Rheumatology Online).
Type I IFN signature gene myeloid and non-myeloid
clusters are differentially altered in rituximab
responders compared with non-responders
Comparison of the gene expression between normal and
myositis subjects before treatment with rituximab indicate
that myositis patients have increased levels of IFN signa-
ture genes at baseline (supplementary Fig. S2, available at
Rheumatology Online). However, in order to assess
www.rheumatology.oxfordjournals.org 1675
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whether the treatment response alters the type I IFN sig-
nature, we calculated the fold change in gene expression
by subtracting the pretreatment gene expression levels
from the post-treatment gene expression levels in the re-
sponder and non-responder groups. We found that
rituximab treatment significantly reduced the type I IFN
gene expression in clusters 12 in responders compared
with non-responders (Fig. 1B). Likewise, rituximab treat-
ment resulted in relatively increased type I IFN gene ex-
pression in clusters 35 in non-responders compared with
FIG. 1 Expression of IFN family genes in rituximab responders and non-responders
(A) Heat map showing the supervised hierarchical clustering of IFN family gene expression in muscle biopsy specimens in
responders and non-responders before and after rituximab treatment. (BD) Fold change in type I IFN genes: (B) myeloid
clusters 12, (C) non-myeloid clusters 35 and (D) all clusters (15) as a result of rituximab treatment in responders and
non-responders (paired t-test *P < 0.05).
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responders (Fig. 1C). Overall, rituximab responders have a
significantly greater reduction of myeloid and non-myeloid
(clusters 15) type I IFN signatures than non-responders
(Fig. 1D).
Muscle-infiltrating B cells and macrophages are also
reduced in responders
Since rituximab targets the B cell marker CD20, we semi-
quantitatively evaluated the presence of these cells in the
muscle biopsy specimens. We found a 20% decrease in
CD19+ B cell numbers in responder muscle biopsies. In
contrast, non-responder patients showed an 53% in-
crease in B cell numbers (Fig. 2A and supplementary
Fig. S3, available at Rheumatology Online). Since B cells
influence macrophage numbers and function, we also
evaluated muscle-infiltrating CD68+ macrophages and
found that these cells were similarly decreased in re-
sponders, by 50%, and increased in non-responders,
FIG. 2 Expression of B cell macrophage and plasma cell markers in rituximab responders and non-responders
Quantification of (A) CD19, (B) CD68, (C) CD138 and (D) IPS-1 staining patterns in responders and non-responders both
before and after treatment with rituximab.
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by 31% (Fig. 2B and supplementary Fig. S3, available at
Rheumatology Online). However, these changes were not
statistically significant.
CD138+ plasma cells are increased in
non-responder patients
CD138 is a recognized plasma cell marker. There was no
difference in the number of CD138+ cells before and after
treatment in responder patients, but non-responders
showed an increase of 71% post-treatment (Fig. 2C).
However, these changes were not statistically significant.
We also stained tissues with an antibody that recognizes
IPS-1, an adaptor triggering RIG-I- and MDA5-mediated
induction of type I IFN. Nuclei of both muscle and infiltrat-
ing cells stained for IPS1, but there were no significant
differences in either group between the pre- and post-
treatment levels (Fig. 2D). Likewise, we stained the tissues
for Mx1 and IFN-b, both of which stained muscle fibres
and infiltrating cells, but these levels did not differ be-
tween responders and non-responders (data not shown).
Discussion
In the present study we have shown that (i) rituximab re-
sponders have higher muscle type I IFN signature genes
before treatment than non-responders, (ii) expression of
type I IFN myeloid signature genes are significantly
decreased in muscle after treatment with rituximab in re-
sponders, (iii) muscle-infiltrating CD19+ B cells and CD68+
macrophages are reduced after treatment with rituximab
in responders and (iv) muscle-infiltrating CD138+ plasma
cells are increased in non-responder patients.
The recently completed RIM clinical trial demonstrated
that although there were no significant differences in pri-
mary and secondary endpoints in the two treatment arms,
83% of the refractory adult and juvenile myositis patients
met the DOI. We divided patients in the present study into
responders and non-responders based on DOI criteria
and assessed muscle gene expression and cellular infil-
trates in an attempt to identify correlations with the re-
sponse to rituximab.
In the RIM study, peripheral B cells were fully depleted
in all patients [3]. We found that muscle-infiltrating B cells
decreased in the responder group but not in the non-
responder group, suggesting that there is either incom-
plete depletion of B cells in the target tissues or increased
repopulation of B cells in the non-responder group. Failure
of B cell depletion in the peripheral pool is associated with
a poor clinical response in RA patients [9].
We recently showed that depletion of peripheral blood
B cells did not correlate with clinical response at week 16,
in that responders and non-responders (based on the
DOI) both reduced CD20+ B cells to a similar extent.
Similar trends were observed for CD20+CD27+ B cells,
except that one non-responder had an increase in
memory B cells at week 16, suggesting that B cell markers
and IFN may have distinct roles in the therapeutic re-
sponse to rituximab [10]. We also found a decrease in
CD20+ cells at week 16 in skeletal muscle, but this did
not reach statistical significance (data not shown).
Because of the small sample size, we could not draw a
meaningful conclusion between CD20+ B cells in the skel-
etal muscle and peripheral blood. Since B cells affect
macrophage numbers, we evaluated CD68+ macro-
phages and found a similar pattern to that for B cells,
suggesting that B cell depletion affects the macrophage
number in muscle tissue.
Several groups have independently shown a marked
increase in type I IFN-inducible transcripts and proteins
in muscle biopsies of clinically active adult and juvenile
myositis patients [5, 1113]. While most studies see a
more dramatic increase in type I INF signatures in juvenile
and adult DM patients, an increase in some PM patients
has also been identified [6, 14].
Walsh et al. [15] also showed that type I IFN-inducible
gene expression in blood reflects disease activity in DM
and PM. Previous studies indicated that there is correlation
between rituximab treatment and both the type I IFN sig-
nature and clinical outcome in RA patients and that clinical
response can be predicted by the type I IFN signature
score [16, 17]. Our study further demonstrates that non-
responders have a higher overall expression of myeloid
type I IFN signature genes and responders have lower
myeloid type I IFN signatures after treatment with rituxi-
mab. Clusters containing myeloid cellspecific genes
such as CD68, ICAM-1, ITGB4, SIGLEC1, etc. are grouped
as myeloid clusters. Rituximab treatment results in a
greater decrease in myeloid clusters (clusters 1 and 2) in
responders than non-responders, whereas non-myeloid
clusters (clusters 35) are decreased in responders and
increased in non-responders. The molecular basis for this
differential response in these two cell types in responders
and non-responders needs further investigation. Recent
studies suggest that type I IFN and myeloid signatures
are candidate markers of disease activity in myositis [18].
We identified five clusters of type I IFN-related genes that
are coordinately regulated, although it is unclear how genes
within each cluster are related to each other functionally.
Overall, clusters that represented the classical IFN-
stimulated genes (clusters 35) were high in non-
responders after treatment with rituximab. This result in
non-responders is consistent with the presence of higher
levels of muscle-infiltrating CD138+ plasma cells in this
group. The decrease in myeloid type I IFN signature
along with the decrease in CD68+ cells in rituximab re-
sponders suggests that reduced activity of innate
immune cells is beneficial to myositis patients, therefore
therapeutic interventions aimed directly at reducing activity
of myeloid cells are likely to be beneficial to myositis
patients.
Previous studies have shown that IFN gene expression
and antibody status might be linked to disease activity. It
has been previously shown that the presence of autoanti-
bodies (e.g. anti-synthetase and anti-Mi-2 autoantibodies)
predicts clinical improvement in patients with refractory
myositis [19]. Further, in a recent study, Reed et al. [20]
showed IFN chemokine (IFNCK) scores were higher at
baseline in subjects with autoantibodies and autoanti-
body-positive subjects had a greater improvement in
1678 www.rheumatology.oxfordjournals.org
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IFNCK scores at 16 weeks after rituximab, suggesting that
both IFNCK high scores and autoantibodies predict clin-
ical improvement in these patients. In our study, most of
the autoantibody-positive patients were responders and
showed greater improvements in overall IFN signature
genes, suggesting that the presence of autoantibodies
and improvements in type I IFN signature may predict
clinical improvement. However, the small sample size in
our study precludes any meaningful correlations with
autoantibody status.
In summary, our study confirms that myeloid and type I
IFN signatures are important in myositis pathogenesis and
rituximab treatment alters these signatures. Rituximab
responders have a greater reduction of the myeloid signa-
ture and non-myeloid type I IFN signature than non-
responders. Some of the limitations of our study include
small sample size, considerable heterogeneity across all pa-
tients and a high degree of variation in the histological evalu-
ations. Future studies are needed to validate these findings
in independent patient cohorts treated with rituximab.
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